Trial begins for Digirad's Cardius X-ACT
Article Thumbnail ImageSeptember 5, 2008 -- Nuclear medicine vendor Digirad of Poway, CA, has begun clinical trials for a new imaging module designed to correct image distortion in cardiac SPECT imaging.
Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Sign in using your social networking account:
Sign in using your social networking

Initial clinical trials for Cardius X-ACT will take place at the University of California, Los Angeles (UCLA) to improve imaging clarity and accuracy and reduce imaging time and radiation dose.

Two other clinical studies are planned for the system, which is based on Digirad's Cardius 3 triple-head SPECT camera.

Digirad hopes to market Cardius X-ACT sometime next year after receiving regulatory clearance.

Related Reading

Novel cardiac SPECT system improves attenuation correction, August 15, 2008

Digirad posts loss in Q2, July 29, 2008

Digirad signs deal with U. of Chicago, April 29, 2008

Digirad Q1 results dip into red, April 24, 2008

Digirad fined by NRC, April 8, 2008

Copyright © 2008